What is… Health Economics and Health Economic Evaluation
In the Wednesday morning session entitled Can’t or Won’t Pay: Health Economics and Bleeding Disorders, Jamie O’Hara describes the many variables and types of analyses that go into health economics assessments.
How to Set Up Chromogenic FVIII and FIX Assays
In the Tuesday afternoon session entitled Role of Chromogenic Assays in Hemophilia Diagnosis, Annette Bowyer explains how to set up chromogenic assays for FVIII and FIX, covering technical aspects such as calibration, accuracy, and quality control in the context of these assays, as well as the cost implications of using them appropriately.
Role of Chromogenic FVIII Assays in Hemophilia A Diagnosis
In the Tuesday afternoon session entitled Role of Chromogenic Assays in Hemophilia Diagnosis, Elizabeth Duncan presented a comparison of clotting assays versus the chromogenic assay in quantifying FVIII, highlighting genotype and phenotype discrepancies and reverse discrepancies.
Women and Girls with Bleeding Disorders
In the Tuesday morning session entitled Women With Bleeding Disorders: Clinical and Psychological Issues, Claire McLintock discussed the effect misinformation and taboos around menstruation can have on the life of women with bleeding disorders.
FXI Deficiency: Genotype, Phenotype and Management
In the Monday afternoon session entitled Rare Bleeding Disorders, Gillian Gidley reviews the genotypes and phenotypes associated with FXI deficiency, shows data on different diagnostic assays, and covers recommendations for management of patients with FXI deficiency.
The Role of the Laboratory in Diagnosis and Management of Inhibitory Antibodies in Hemophilia
In the Monday morning session entitled Inhibitors: Clinical Aspects, Jan Astermark described the different diagnostic assays laboratories can carry out to measure inhibitors.
Rare Bleeding Disorders: Overview of Clinical Assessment and Diagnosis
In the Monday afternoon session entitled Rare Bleeding Disorders, Flora Peyvandi gives an overview of RBDs in Europe and discusses current technical limitations in laboratory testing, presents current treatments, and also discusses novel treatment strategies.
Gene Therapy for Haemophilia: What, Why, How, When, Who, and Where?
In the Sunday afternoon session entitled Gene Therapy: Back to Basics, Glenn Pierce explains the state of the art and the future prospects of gene therapy, gene editing, and cell therapy, in the context of hemophilia.
State of the Art of the XXXIII International Congress of the World Federation of Hemophilia
The freely available special Haemophilia Journal supplement dedicated to the WFH 2018 World Congress Glasgow (Vol 24, Issue Supplement S6 Pages 1–94) features reviews of the state of the art of each of the topics of the medical plenaries and sessions at the Congress, written by featured speakers.
Abstracts of the XXXIII International Congress of the World Federation of Hemophilia
The freely available special Haemophilia Journal supplement dedicated to the WFH 2018 World Congress Glasgow (May 2018, Vol 24, Issue Supplement S5 Pages 1–218) features abstracts of many of the posters presented at the Congress, including Late-Breaking Abstracts and those selected for presentation as Free Papers.
Inhibitors in Hemophilia: A Primer
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Traditional Chinese Inhibitors are a serious complication of hemophilia caused by an immune response to clotting factor concentrates. Treatment of inhibitors is one of the biggest challenges in hemophilia care today. This primer explains our current understanding of […]
Report on the Annual Global Survey 2017
Compiled annually, the Annual Global Survey (AGS) provides demographic and other data on people with hemophilia, von Willebrand disease, other rare factor deficiencies, and inherited platelet disorders throughout the world.